Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin (5 mg/mL) in 50 mL of 5% Dextrose, For...
FDA Drug Recall #D-0704-2018 — Class II — March 27, 2018
Recall Summary
| Recall Number | D-0704-2018 |
| Classification | Class II — Moderate risk |
| Date Initiated | March 27, 2018 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | AuroMedics Pharma LLC |
| Location | East Windsor, NJ |
| Product Type | Drugs |
| Quantity | 46824 bags |
Product Description
Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin (5 mg/mL) in 50 mL of 5% Dextrose, For Intravenous Infusion, Rx only, Manufactured By: Aurobindo Pharma Limited IDA Pashamylaram - 502307, India, Manufactured for: AuroMedics Pharma, LLC, NDC 55150-243-46.
Reason for Recall
Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap
Distribution Pattern
US Nationwide
Lot / Code Information
Lot/Batch #'s: CLF160002, CLF160004, CLF160005 exp May 2018; CLF160006, CLF160007 exp June 2018; CLF170027 exp July 2019; CLF170029 exp August 2019
Other Recalls from AuroMedics Pharma LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0020-2023 | Class II | Fondaparinux Sodium Injection, USP, 7.5 mg per ... | Sep 30, 2022 |
| D-0013-2023 | Class II | Acyclovir Sodium Injection, 500mg/10mL (50mg/mL... | Sep 26, 2022 |
| D-1551-2022 | Class III | Tranexamic Acid Injection, USP, 1000mg per 10 m... | Sep 26, 2022 |
| D-0556-2022 | Class I | Polymyxin B for Injection USP, 500,000 Units pe... | Jan 26, 2022 |
| D-0248-2021 | Class II | Acetaminophen Injection 1,000 mg per 100 mL (10... | Dec 30, 2020 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.